GLP-1 medicolegal exposure under review in JAAD November issue

The November 2026 issue of the Journal of the American Academy of Dermatology will carry an analysis of medicolegal liability patterns tied to GLP-1 receptor agonist prescribing, the journal confirmed with its table-of-contents release.

The article, titled "Evolving medicolegal liability patterns in GLP-1 receptor agonist prescribing," runs in JAAD Vol. 95, Issue 5. Authors are Ghassan Barnawi, Camelia Amara, and Shari R. Lipner, MD, PhD. Lipner, an associate professor of dermatology at Weill Cornell Medicine in New York, has built a track record of medicolegal publications in the specialty, including earlier analyses of skin cancer litigation and cosmetic procedure claims.

What does the paper examine?

The paper targets the shifting terrain of liability exposure as GLP-1 receptor agonists — led by semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — move out of endocrinology into broader prescribing practice. Semaglutide cleared the FDA for type 2 diabetes in December 2017 and for chronic weight management in June 2021; tirzepatide followed for diabetes in May 2022 and for obesity in November 2023. Each label expansion pulled in fresh prescriber groups, each of which inherited a new documentation and informed-consent workload.

Why does the topic matter for dermatologists?

Dermatology now sits inside that workflow on two fronts. Patients already on these drugs arrive at the clinic with medication histories that shape surgical planning, drug-interaction checks, and comorbidity management. Some dermatologists also prescribe or co-manage the drugs for conditions where weight loss carries clinical benefit — psoriasis with obesity, hidradenitis suppurativa, acanthosis nigricans — or to address known cutaneous adverse events. Injection-site reactions, alopecia, and rapid-onset skin laxity after major weight loss all appear in the FDA Adverse Event Reporting System.

How has Lipner's group tackled medicolegal work before?

Lipner's prior publications run on a consistent method: Westlaw and LexisNexis queries for case law involving dermatologists, FAERS pulls for adverse-event signals, and state-board action reviews. The output typically sorts claims by allegation type, indemnity payment, and year of incident. Applied to GLP-1 RA prescribing, the same framework would sort claims by who prescribed — endocrinologist versus primary care, dermatologist, ob-gyn — by what went wrong, and by how cases resolved.

Where does the JAAD placement fit?

JAAD's editorial cadence has long included medicolegal analyses alongside its clinical evidence coverage. The November placement puts the GLP-1 paper in front of dermatologists whose patients already take these drugs at scale — U.S. weekly prescriptions cleared 1.6 million by mid-2024 according to separate market tracking — and whose own prescribing, monitoring, or referral decisions intersect with the class every clinic day. The journal reaches a U.S. dermatology audience that already drives a meaningful share of GLP-1 prescriptions through its obesity-comorbidity referrals.

What should practices do next?

The paper arrives in time to set documentation templates and consent forms for the next prescribing year. Practices without a GLP-1 protocol now have a published medicolegal baseline to draft against; practices with protocols in place get a benchmark to audit. Watch for the formal November release and the full text on the JAAD portal, where the journal posts accepted manuscripts ahead of print.

GLP-1 prescribing continues to outpace the medicolegal literature that traditionally lags new drug classes by three to five years. Court records accumulate slowly, so the claim pool Lipner and co-authors are mapping is still forming. Follow-up papers from the same group and from independent malpractice trackers will reveal whether the pattern identified in November expands, plateaus, or shifts toward dermatology claims specifically.